Defence Therapeutics (TSE:DTC) has released an update.
Defence Therapeutics Inc. recently highlighted an interview with its Chief Scientific Officer, Dr. Moutih Rafei, on Money Talk Radio, where he discussed the company’s innovative ACCUM technology for cancer treatment. The biopharmaceutical firm is advancing immune-oncology vaccines and drug delivery technologies aimed at enhancing the efficacy of cancer and infectious disease treatments. Defence is capturing the attention of the investment community as it progresses in engineering next-generation vaccines and ADC products.
For further insights into TSE:DTC stock, check out TipRanks’ Stock Analysis page.
